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OBJECTIVES: People with T2D insufﬁciently controlled on oral
antidiabetic drugs often delay the start of sc insulin (SCI) treat-
ment for different reasons. This cross-sectional prospective
survey (EC approved) aimed at investigating whether these
patients have different levels of acceptance regarding SCI.
METHODS: Basic data (age, gender, duration of DM, BMI;
HbA1c, HOMA index), social status were recorded. Aversions to
SCI were investigated by using the Barriers to Insulin Question-
naire (BIT) which covers 5 dimensions using 14 questions. The
ﬁrst 3 principal components of the 5 BIT domains were analyzed
with Ward’s Minimum Variance Clustering Algorithm. The
number of clusters were determined with Pseudo T Statistic, CC
Criteria and judgment.The BIT domains were Z standardized
and tabulated against the cluster. T-values between -2 and 2 are
reported as 0; low or high t-values between -5 and -2 or 2 and
5 as ‘-’ and ‘+’, respectively; very low or very high t-values below
-5 or greater than 5 are reported as ‘+ +’ and ‘- -’. The associa-
tion between the clusters and certain medical and sociodemo-
graphic variables was analyzed exploratively with the Chi sq test
for nominal/ordinal variables and Kruskal-Wallis test for con-
tinuous variables. RESULTS: 532 patients were eligible
for analysis (male 354/age 56.5  8.8/duration of diabetes
6.7  6.1/BMI 32.5  6.6/HbA1c 8.3  1.5); 5 clusters were
found. In cluster 1 we ﬁnd patients having positive expectations
regarding SCI but fear of burden with insulin treatment and
hypoglycemia. Cluster 2 patients had no barriers. Cluster 3
patients are similar to cluster 2, but have some fear of hypogly-
cemia. Type 4 patients have strong barriers concerning insulin
injection, fear of stigmatization and hypoglycemia. Negative
expectations are characteristic for the patients in cluster 5. CON-
CLUSION: The BIT results have a major impact on the deﬁnition
of the clusters; educational level has an impact as well. The
patients did not differ in their glycemic control.
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OBJECTIVES: To test face, content and psychometric validity of
the DSC-R, a widely-used patient reported outcome (PRO)
measure of diabetes symptom distress, in line with FDA Guid-
ance. METHODS: Face and content validity of the DSC-R was
evaluated according to draft FDA guidance. Interviews with 20
US patients with Type-2 Diabetes Mellitus were conducted to
assess the comprehensibility and acceptability of the English
language DSC-R version. Patients were asked open-ended ques-
tions about their diabetes symptoms and symptom-bother before
cognitive debrieﬁng. Psychometric validity of the DSC-R was
assessed using blinded data from 2 large scale trials of approxi-
mately 4000 patients each. RESULTS: All symptoms spontane-
ously reported by patients are included in the DSC-R. Upon
probing, patients reported experiencing symptoms of itchy skin,
increased hunger, sweats and gender-speciﬁc sexual symptoms
not directly included in the DSC-R. Patients found all DSC-R
questions easy to understand and answer, with the exception of
“dull head” and “frequent voiding”. Both items had been inac-
curately reworded when translated from Dutch to English. These
have been corrected through subsequent linguistic validation.
Patients generally understood the instructions and response
options. Patients used various recall periods to answer the
DSC-R other than the 4 weeks speciﬁed. Conﬁrmatory factor
analysis and multi-trait analysis indicated that the scoring of the
DSC-R has strong construct validity and reliability. DSC-R
domains discriminated among patients who differed according to
body mass index (p < 0.0001) and C-reactive protein levels
(p < 0.0001). CONCLUSION: The DSC-R items are regarded
relevant and easily understood by patients. Revision of the recall
period may be considered, in view of FDA Guidance. DSC-R
demonstrated excellent psychometric properties when tested in
two large-scale diabetes clinical trials.
PDB74
EFFECTS OF AN INTENSIFIEDTHERAPY WITH INSULIN
GLARGINE AND INSULINE GLULISINE ON PATIENT
REPORTED OUTCOMES IN DIABETES MELLITUS
Daikeler R1, Hoegy B2
1Specialist in Internal Medicine, Diabetologist, Sinsheim, Germany,
2Sanoﬁ-Aventis Germany GmbH, Bad Soden, Germany
OBJECTIVES: Intensive conventional insulin therapy (ICT) is to
be considered as the gold standard for treatment of type 1 and
type 2 diabetes mellitus. However, conventional insulin prepara-
tions do not always result in a sufﬁcient outcome. An observa-
tional study was conducted to assess efﬁcacy, tolerability, quality
of life and treatment satisfaction of patients with type-1 and
type-2 diabetes over a period of 6 month. METHODS: A total of
1447 type-1 and 5695 type-2 diabetes patients with different
prior insulin treatments were switched to a combination of
insulin analogues insulin glargine and insulin glulisine. Clinical
efﬁcacy and safety was evaluated by blood glucose and HbA1c
values and by incidence of adverse events. Patient reported out-
comes (PRO) were measured with a visual analogue scale (VAS)
and the diabetes treatment satisfaction questionnaire (DTSQs).
Six categories of quality of life were evaluated from physician’s
perspective by means of 5-stepped Likert-Scale. RESULTS: Mean
blood sugar values and HbA1C value signiﬁcantly decrease
during the observational period in both patient groups. Total
scores for quality of life were improved about 30% in mean for
diabetes type 1 and about 32% in mean for diabetes type 2,
respectively. VAS-scores (0 to 100) improved from 41.9  22.0
to 19.6  14.1 for diabetes type 1 and from 49.6  20.9 to
22.8  16.0 for diabetes type 2, respectively. DTSQs total scores
increased from 20.7  6.7 to 29.3  5.1 and from 19.1  6.6 to
28.4  5.2, respectively (p < 0.0001 for all differences). CON-
CLUSION: Basal-bolus therapy with a combination of insulin
glargine and insulinglulisine improved treatment satisfaction and
quality of life in accordance with clinical efﬁcacy in patients with
type 1 and type 2 diabetes pretreated with ICT. The analysis was
funded by Sanoﬁ aventis Germany.
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OBJECTIVES: The objective of the study was to translate and
linguistically validate the Insulin Treatment Satisfaction Ques-
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